• Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    Czechia Germany Italy The Netherlands Poland Slovakia +1

  • Short-course (7‑day) versus standard 14‑day ciprofloxacin treatment for men with serious urinary tract infection

    Recruiting

    3 1 1
    Investigated Drugs:
    Belgium

  • A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Austria Belgium Bulgaria Czechia Estonia Finland +14

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Czechia Denmark France Germany +9

  • Evaluation of pembrolizumab and bevacizumab in patients with metastatic cervical cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

  • Zongertinib for Cancer in Patients Eligible for Early Access Treatment

    Recruiting

    2 1 1
    Investigated Drugs:
    Finland

  • Total-Body PET with [18F]Flutemetamol in Patients with Post-COVID Syndrome (Long COVID)

    Recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

  • RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

    Recruiting

    3 1
    Investigated Diseases:
    Belgium Czechia France Germany Hungary Italy +3

  • A study to evaluate the effect of nolasiban on uterine contractions in women undergoing IVF or ICSI treatments

    Recruiting

    2 1
    Spain

  • Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

    Recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia France Germany Poland Spain

powered by